Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARKG vs ARKK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARKK Wins Head-to-Head Institutional Verdict (1–0 across 6 Pillars · 2–1 Matrix Metrics)

ARKK Overall Winner 6-Pillar Tally: ARKG 0 – 1 ARKK (5 Tie) Matrix Metrics: ARKG 1 – 2 ARKK

As of Nov 16, 2026, ARK Innovation ETF (ARKK) is the stronger overall head-to-head candidate over ARK Genomic Revolution ETF (ARKG) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Options & Positioning). ARKG carries a Unified Composite Score of 48.6/100 (HOLD) at $40.92 (N/M Forward P/E, N/A operating margin), whereas ARKK carries 56.8/100 (HOLD) at $71.74 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: ARKG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2); meanwhile ARKK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARKG vs ARKK
ARKG Cboe BZX
ARK Genomic Revolution ETF
Institutional Equity
$40.92
-5.28% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.08β · 70% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 26.0 Fund 45.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.2 · SMA20: $48.17 · SMA50: $49.46
ARKK Cboe BZX Head-to-Head Winner
ARK Innovation ETF
Institutional Equity
$71.74
-4.33% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.18β · 53% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.7%), weak momentum, RSI 35
RSI-14: 34.7 · SMA20: $79.92 · SMA50: $84.42

6-Pillar Scorecard Institutional Category Breakdown (ARKG 0 – 1 ARKK)

Columns: Metric · ARKG · ARKK
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ARKK
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 47.2% (38th %ile) 37.9% (25th %ile)
Put/Call OI Skew N/A 1.39x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARKG (1) vs ARKK (2)
Institutional Metric ARKG ARKK Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
48% ($25–$59) 28% ($63–$95) Stronger Trend ARKG
Beta / 30D Volatility
Risk Regime
2.08β · 70% Vol 2.18β · 53% Vol Lower Realized Risk ARKK
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 56.8 / 100 (HOLD) Higher Composite ARKK
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARKK +0.24 pp
ARKG: -12.38% · ARKK: -12.14%
3M Horizon ARKG +4.06 pp
ARKG: -5.3% · ARKK: -9.36%
6M Horizon ARKG +49.29 pp
ARKG: +45.57% · ARKK: -3.72%
1Y Horizon ARKG +58.27 pp
ARKG: +51.33% · ARKK: -6.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARKG vs ARKK. Trailing 12-month operating profitability (ARKG N/A vs ARKK N/A) and valuation multiples (ARKG N/M vs ARKK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ARKG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ARKK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARKG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 47.2%
IV Percentile 38th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ARKG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARKK CONSOLIDATION
30d in phase · OBV DISTRIBUTION
Current IV 37.9%
IV Percentile 25th %ile
Put/Call OI Skew 1.39x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ARKK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARKG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ARKK Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARKG vs ARKK Key Questions & Quantitative Answers

As of Nov 16, 2026, ARK Innovation ETF (ARKK) is the stronger overall head-to-head candidate over ARK Genomic Revolution ETF (ARKG) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Options & Positioning). ARKG carries a Unified Composite Score of 48.6/100 (HOLD) at $40.92 (N/M Forward P/E, N/A operating margin), whereas ARKK carries 56.8/100 (HOLD) at $71.74 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ARKG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2); meanwhile ARKK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARKG and ARKK split Growth & Scale metrics: ARKG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ARKK at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ARKG generates N/A in USD-normalized revenue versus N/A for ARKK. In operating R&D and SG&A reinvestment, ARKG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARKK.

ARKG and ARKK trade at balanced relative valuation multiples. ARKG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ARKK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARKG (N/A ROE) versus ARKK (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ARKG carries 47.2% implied volatility (38th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.08β · 70% Vol realized risk). By comparison, ARKK carries 37.9% implied volatility (25th %ile, Compressed (<25th %ile)), a 1.39x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.18β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.